Finasteride for the treatment and control of benign prostatic hyperplasia: Summary of phase III controlled studies

P. Grino; E. Stoner; G. L. Andriole; R. Boake; B. R. Bracken; W. Brannan; R. C. Bruskewitz; C. E. Cox; G. R. Cunningham; P. C. Devine; P. F. Schellhammer

doi:10.1159/000475328

Finasteride for the treatment and control of benign prostatic hyperplasia: Summary of phase III controlled studies

P. Grino, E. Stoner, G. L. Andriole, R. Boake, B. R. Bracken, W. Brannan, R. C. Bruskewitz, C. E. Cox, G. R. Cunningham, P. C. Devine, P. F. Schellhammer

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

The efficacy and safety profiles of finasteride were tested in 1,645 patients with benign prostatic hyperplasia (BPH) over a 12-month period. The following effects were observed: (1) a 60-80% reduction in serum dihydrotestosterone levels; (2) a 20% reduction in prostate volume; (3) significant increases in the maximum urinary flow rate compared with placebo; and (4) significant improvement in urinary symptoms, particularly obstructive symptoms. All effects were well maintained for the entire duration of the study. Finasteride had a good safety profile and was well tolerated.

Original language	English
Pages (from-to)	24-28
Number of pages	5
Journal	European Urology
Volume	25
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1159/000475328
State	Published - 1994

Keywords

5α-Reductase
Androgens
Dihydrotestosterone
Urinary flow rate

Access to Document

10.1159/000475328

Cite this

@article{7428208d32aa4637a50e68fdff8e66a6,

title = "Finasteride for the treatment and control of benign prostatic hyperplasia: Summary of phase III controlled studies",

abstract = "The efficacy and safety profiles of finasteride were tested in 1,645 patients with benign prostatic hyperplasia (BPH) over a 12-month period. The following effects were observed: (1) a 60-80% reduction in serum dihydrotestosterone levels; (2) a 20% reduction in prostate volume; (3) significant increases in the maximum urinary flow rate compared with placebo; and (4) significant improvement in urinary symptoms, particularly obstructive symptoms. All effects were well maintained for the entire duration of the study. Finasteride had a good safety profile and was well tolerated.",

keywords = "5α-Reductase, Androgens, Dihydrotestosterone, Urinary flow rate",

author = "P. Grino and E. Stoner and Andriole, {G. L.} and R. Boake and Bracken, {B. R.} and W. Brannan and Bruskewitz, {R. C.} and Cox, {C. E.} and Cunningham, {G. R.} and Devine, {P. C.} and Schellhammer, {P. F.}",

year = "1994",

doi = "10.1159/000475328",

language = "English",

volume = "25",

pages = "24--28",

journal = "European Urology",

issn = "0302-2838",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Finasteride for the treatment and control of benign prostatic hyperplasia

T2 - Summary of phase III controlled studies

AU - Grino, P.

AU - Stoner, E.

AU - Andriole, G. L.

AU - Boake, R.

AU - Bracken, B. R.

AU - Brannan, W.

AU - Bruskewitz, R. C.

AU - Cox, C. E.

AU - Cunningham, G. R.

AU - Devine, P. C.

AU - Schellhammer, P. F.

PY - 1994

Y1 - 1994

N2 - The efficacy and safety profiles of finasteride were tested in 1,645 patients with benign prostatic hyperplasia (BPH) over a 12-month period. The following effects were observed: (1) a 60-80% reduction in serum dihydrotestosterone levels; (2) a 20% reduction in prostate volume; (3) significant increases in the maximum urinary flow rate compared with placebo; and (4) significant improvement in urinary symptoms, particularly obstructive symptoms. All effects were well maintained for the entire duration of the study. Finasteride had a good safety profile and was well tolerated.

AB - The efficacy and safety profiles of finasteride were tested in 1,645 patients with benign prostatic hyperplasia (BPH) over a 12-month period. The following effects were observed: (1) a 60-80% reduction in serum dihydrotestosterone levels; (2) a 20% reduction in prostate volume; (3) significant increases in the maximum urinary flow rate compared with placebo; and (4) significant improvement in urinary symptoms, particularly obstructive symptoms. All effects were well maintained for the entire duration of the study. Finasteride had a good safety profile and was well tolerated.

KW - 5α-Reductase

KW - Androgens

KW - Dihydrotestosterone

KW - Urinary flow rate

UR - http://www.scopus.com/inward/record.url?scp=0028366217&partnerID=8YFLogxK

U2 - 10.1159/000475328

DO - 10.1159/000475328

M3 - Article

C2 - 7507052

AN - SCOPUS:0028366217

SN - 0302-2838

VL - 25

SP - 24

EP - 28

JO - European Urology

JF - European Urology

IS - SUPPL. 1

ER -

Finasteride for the treatment and control of benign prostatic hyperplasia: Summary of phase III controlled studies

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this